Life Sciences INDUSTRIES

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.


Recognized as a leading life sciences practice, WilmerHale has represented life sciences clients across the United States and Europe for more than four decades. From biotechnology, pharmaceutical, diagnostic and medical device companies at all stages of growth to other institutions in the space, including venture capitalists, investment banks, universities and others, we understand the business of our life sciences clients and the changing regulatory and competitive demands they face.

Contacts

Sort By
Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

stuart.falber@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Der Marderosian, Lia

Lia Der Marderosian

Co-Chair, Corporate Practice Group

+1 617 526 6982 (t)

lia.dermarderosian@wilmerhale.com

johnson-brian.jpg

Brian A. Johnson

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

+1 212 937 7206 (t)

brian.johnson@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Capabilities

WilmerHale's Life Sciences Practice has extraordinary range, and the majority of our lawyers devote a significant portion of their practice to areas critical to life sciences clients. The firm's multi-disciplinary teams work seamlessly to handle a broad range of matters for clients, including corporate finance, licensing and strategic alliances, litigation, mergers and acquisitions, intellectual property, Food and Drug Administration (FDA), competition and other regulatory matters, and securities fraud. Our lawyers advise on venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protect clients' innovations through patent prosecution and portfolio development; and defend their interests in enterprise-critical patent litigation. We also represent life sciences clients in dealings with the United States and other governments on regulatory matters, including issues before the FDA and other agencies, merger clearance and enforcement actions, and public policy and strategy. Read about some of our recent life sciences transactions.

Our Life Sciences Practice includes corporate lawyers who have helped thousands of entrepreneurs successfully launch their businesses; raise billions in financing; and take their companies to sale, the public markets and/or through drug commercialization. We have a longstanding tradition of representing emerging companies and entrepreneurs across industries, and routinely offer the strategic advice and sharp business perspectives that are critical to our clients' success. Learn about our startup practice at WilmerHaleLaunch.com.

Publications & News

View

December 9, 2016

WilmerHale Listed Among Top Thought Leaders in Life Sciences Law Firm Index

Lake Whillans evaluated firms based on the strength of elements such as white papers, contributions to third-party media and speaking engagements.

November 17, 2016

Rise of digital DNA raises biopiracy fears

Bruce Manheim is quoted in this article published in Science magazine. The article describes how the use of digital DNA may be regulated by various nations under the Nagoya Protocol and may lead to allegations of biopiracy.

November 11, 2016

WilmerHale Advises Memorial Sloan Kettering, The Rockefeller University and Weill Cornell Medicine in Establishment of Bridge Medicines

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they established a new drug discovery company called Bridge Medicines.

November 8, 2016

Regulation of Synthetic Biology Under the Nagoya Protocol

An article by Bruce Manheim, published in Nature Biotechnology, considers whether digital sequence information from genetic resources in foreign countries will be subject to the access and benefit-sharing requirements of the Nagoya Protocol and other international agreements.

November 8, 2016

WilmerHale Reps Infinity Pharma in $28M Licensing Agreement with Verastem

The WilmerHale deal team was led by Partners Belinda Juran and Steven Singer and included Associate Alex Civetta.

October 13, 2016

WilmerHale Reps Ocular Therapeutix™ in Strategic Collaboration With Regeneron

Ocular Therapeutix, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals, Inc.

October 12, 2016

Freedom to Utilize Genetic Resources? The Nagoya Protocol Two Years Later

An article by Bruce Manheim, published as a WilmerHale Client Alert and republished by Intellectual Property Watch, discusses the Nagoya Protocol and how over the past two years—as various nations have adopted new provider and user measures—the Protocol's legal framework has begun to coalesce into an international regulatory scheme governing access to and use of genetic resources for research and development.

October 10, 2016

Technical and Scientific Experience

Our ability to provide superior legal representation to technology companies is greatly enhanced by the academic and industry experience of our lawyers in a wide variety of technical and scientific fields.    

October 6, 2016

WilmerHale Advises Catabasis Pharmaceuticals in Closing of $11.5M Offering of Common Stock

The WilmerHale deal team was led by Partner Rosemary Reilly and included Counsel Jeffries Oliver-Li, Associate Timothy Kulis, and Attorney Heidi Treiber.

October 4, 2016

Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement

WilmerHale client Summit Therapeutics plc and Sarepta Therapeutics announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States.

Recognition

  • Chambers USA: America's Leading Lawyers for Business - Named WilmerHale a top law firm for life sciences from 2007-2016 and quoted sources as saying our attorneys are "consistently excellent," "very responsive" and "continue to stand out," and that WilmerHale is "a very strong firm" that is "in the top 1%" in the area of life sciences. 
  • Chambers Global - Recognized WilmerHale as a leader in life sciences from 2013-2016 and quoted sources as saying that the firm has an "outstanding US practice coupled with international reach" and "a team of lawyers with a valuable scientific background."
  • Chambers Europe - Recognized WilmerHale as a leader in life sciences in Germany in its 2013-2015 editions.
  • Lake Whillians - Named WilmerHale among the top three Best Life Sciences Law Firms for 2016 in its inaugural Life Science Index, and selected WilmerHale as the top firm in the patent category. The firm was also named among the top 10 law firms nationally for life sciences thought leadership.
  • Law360 - Named WilmerHale "Life Sciences Practice Group of the Year" for 2013 in its annual competition, which recognizes five firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year.
  • LMG Life Sciences - Ranked the firm in its 2012-2016 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations, and named WilmerHale a "Lifecycle Firm." In 2013, WilmerHale was named the winner of the "Canadian Impact Deals of the Year" award, in recognition of its representation of Enobia Pharma in its acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP - Recognized WilmerHale as one of the best in the United States for life sciences from 2013-2016. In both 2013 and 2016, WilmerHale was named the "Patent Contentious Firm of the Year" and in 2013, the "Pharmaceutical IP Litigation Firm of the Year."
  • The American Lawyer - Placed WilmerHale on its 2015 "A-List" as one of the United States' leading law firms, marking the 12th year the firm received that recognition.
  • The American Lawyer - Recognized WilmerHale as its 2014 "IP Litigation Department of the Year." This was the second time that WilmerHale was named a winner and the third time the firm was named a finalist in this contest since its launch in 2004.
  • The BTI Consulting Group Inc. - Named WilmerHale among the top 10 law firms for having strong and lasting client relationships with the pharma industry in its BTI Power Rankings 2016 report.
  • The Legal 500 US - Ranked WilmerHale among the top law firms for life sciences from 2013-2016 and quoted sources as saying the firm "brings a great deal of experience to any situation" and "has access to additional expertise/resources to help solve any problem."
  • The National Law Journal - Named WilmerHale to its 2012-2015 Intellectual Property Hot List, which honors firms that demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News - Best Lawyers® - Recognized the firm in its 2014-2017 "Best Law Firms" lists in the first tier nationally for biotechnology law, corporate law, intellectual property litigation, patent law, securities and venture capital law. In 2017, WilmerHale received first-tier metropolitan rankings in Boston intellectual property litigation, patent law, technology law and venture capital law; in Colorado for intellectual property litigation; in New York for biotechnology law and corporate law; in San Jose for patent litigation; and in Washington DC for intellectual property litigation.